# Rituximab not superior to azathioprine for EGPA remission maintenance

Source: [Medical research : nature.com subject feeds](https://www.nature.com/articles/s41584-026-01465-4) · 2026-11-10 · Medicine
Page: https://themorning.science/story/rituximab-not-superior-to-azathioprine-for-egpa-remission-maintenance-4fbd5617b3c2be5b
Kind: research · Impact: medium

## In brief

- Headline reports that rituximab was not superior to azathioprine for maintaining remission in EGPA.
- No summary is available in the source, so trial design and results are not described.

## Why it matters

Clinicians choosing maintenance therapy for eosinophilic granulomatosis with polyangiitis (EGPA) may find the comparison relevant, though the available source gives no further detail.

## Coverage

- [Rituximab not superior to azathioprine for EGPA remission maintenance](https://www.nature.com/articles/s41584-026-01465-4) — Medical research : nature.com subject feeds, 2026-11-10

Tags: egpa, rituximab, azathioprine, vasculitis, rheumatology

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science